https://www.selleckchem.com/products/isrib.html
ate cancer. Survival from metastatic cutaneous melanoma is substantially lower than for localized disease. Treatments for metastatic melanoma have been limited, but remarkable clinical improvements have been reported in clinical trials in the last decade. We described the characteristics of US patients diagnosed with cutaneous melanoma during 2001-2013 and assessed trends in short-term survival for distant-stage disease. Trends in 1-year net survival were estimated using the Pohar Perme estimator, controlling for background mortality with
Like
Comment
Share